The dawn of a new era of targeted lipid-lowering therapies

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Lifestyle modifications are crucial but often insufficient for optimal lipid control in cardiovascular disease.
• Low-density lipoprotein (LDL) is a confirmed causal factor in atherosclerosis development.

Purpose of the Study:

• To review recent advancements in lipid-lowering therapies and novel therapeutic targets.
• To discuss emerging strategies for managing LDL, triglyceride-rich lipoproteins, and lipoprotein(a).

Main Methods:

• Review of recent human genetic findings identifying novel lipid-lowering targets.
• Analysis of advancements in biotechnology for drug development.
• Examination of new biological, RNA-directed, and small-molecule agents.
• Assessment of innovative targeting strategies and gene-editing approaches.

Main Results:

• Identification of novel therapeutic targets such as apolipoprotein C-III, angiopoietin-like proteins 3 and 4, apolipoprotein V, and ATP citrate lyase.
• Development of new treatments for triglyceride-rich lipoproteins and lipoprotein(a).
• Improved efficacy and tolerability of novel lipid-lowering interventions.
• Emergence of gene-editing as a future therapeutic avenue.

Conclusions:

• Recent discoveries in genetics and biotechnology are revolutionizing lipid management for cardiovascular disease.
• A diverse array of novel therapeutic agents and strategies are enhancing the control of lipid risk factors.
• These advancements offer promising new avenues for practical patient care and improved cardiovascular outcomes.